

WHO Interim Guidelines for the Treatment of gambiense Human African Trypanosomiasis

Summary of declared interests

Conflicts of interest were managed as follows:

- Experts participating in the process were required to complete the WHO Declaration of Interest (DOI) form before they commenced their work for WHO, and to promptly notify WHO if any change in the disclosed information occurred during the course of the guidelines development. The completed DOI forms were reviewed by the WHO Secretariat with a view to managing disclosed interests in the field of HAT.
- At the meeting of the Guidelines Development Group in December 2018, all meeting participants verbally disclosed any interests declared to the rest of the group. Hence, the GDG was aware of any existing interests among its members.
- All declarations of interest were reviewed by the WHO Secretariat. It was decided that all experts could participate in the process as no member had financial or commercial interests related to HAT therapeutics, and that there were no significant intellectual conflicts of interests that would exclude any member from fully participating in the guideline development process. As a result, options for conditional participation, partial exclusion or total exclusion of any member were not discussed.

All relevant declared interests are summarized below.

Table. Interests declared by members of the Guideline Development Group and other experts participating in the process

Name	Institution	Nature of interest	year
Andreas Lindner	Institute of Tropical Medicine and International Health, Berlin	Independent expert in a Scientific Advisory Group on fexinidazole at the EMA	2018
Erick Mwamba	Ministry of Health, DRC	None declared	
François Chappuis	Hôpitaux Universitaires de Genève	None declared	
Jorge Seixas	Portuguese Institute of Hygiene and Tropical Medicine, Lisbon	Independent expert in a Scientific Advisory Group on fexinidazole at the EMA Collaboration with DNDi for fexinidazole trial on rhodesiense HAT.	2018
Leon Kazumba	University of Kinshasa	Member of Data Safety Monitoring Board for DNDi trials on fexinidazole and oxaborol	2012 to date
Michael Barrett	University of Glasgow	None declared	
Olema Erphas	Ministry of Health, Uganda	None declared	
Veerle Lejon	Institut de Recherche pour le Développement, Montpellier	Training DNDi clinical trial teams on laboratory aspects, as consultant. Collaboration with DNDi for fexinidazole trial on rhodesiense HAT. Travel expenses covered by DNDi for presentations at ASTMH meetings.	2012 2018 2014, 2016, 2018
Elie Akl (methodologist)	American University of Beirut, Lebanon	None declared	
Gemma Villanueva (evidence review)	Cochrane Infectious Diseases Group, UK	None declared	
Hanna Bergman (evidence review)	Cochrane Infectious Diseases Group, UK	None declared	